Total raised
—
Last: Undisclosed 2017-05
Stage
Seed
Founded
2014
Headcount
6
HQ
Sector
Health Tech & Life Sciences
About
HepaRx is developing a small molecule cancer drug that inhibits heparanase (Hpa) enzymatic activity in order to stop the spread of cancer cells. The company is employing the Hpa crystal structure for drug design and development. Hpa has been evaluated extensively as a target for drug development, showing substantial involvement in disease progression and high-level expression in various cancer types including pancreatic, lung, breast, and mesothelioma. HepaRx has been operating in the framework of the biotech accelerator FutuRx.
Funding history · 1 round · — total
2017-05
Undisclosed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
oncologydrug-designpharma-companiesbiopharmaceutical